Global Ulcerative Colitis Treatment market research report provides the details about Industry Overview, Chain structure, Market Competition, Market Size and Share, SWOT Analysis, Technology, Cost, Raw Materials, Consumer Preference, Development and Trends, Regional Forecast, Company and Profile and Product and Service. Ulcerative Colitis Treatment market research report also gives information on the Trade Overview, Policy, Regional Market, Production Development, Sales, Regional Trade, Business Operation Data, Market Features, Investment Opportunity, Investment Calculation and other important aspect of the industry. Continue reading →

PFAS CONTAMINATION Two of the 'forever chemicals' have been studied widely and show a wide range of harmful effects. A Pitt researcher is helping to tackle the problem: What do we do about the other 4,000+? By Oliver Morrison | December 2, 2020 Carla Ng , pictured in her lab in February 2020, is one of the few scientists trying to tackle the problem of how to address potential contamination from thousands of PFAS chemicals at once Continue reading →

NEWARK, Calif., Dec. 1, 2020 /PRNewswire/ --Protagonist Therapeutics, Inc. Continue reading →

Although biopharma executives leave for many reasons and at any time, there is a tendency to make shifts toward the end of the year. Continue reading →

December 04, 2020 02:00 ET | Source: Hofseth Biocare ASA NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Reference is made to the stock exchange announcements from Hofseth BioCare ASA (the "Company") on 16 October 2020 regarding completion of a private placement raising gross proceeds of NOK 200 million (the "Private Placement") and on 11 November 2020 regarding an application to Oslo Brs for a transfer of listing of the Company's shares from Euronext Expand to Oslo Brs (the "Transfer of Listing"). The Financial Supervisory Authority of Norway (Nw. Finanstilsynet) has on 3 December 2020, approved the Company's prospectus (the "Prospectus") prepared in connection with; (i) a subsequent offering of up to 4,938,271 new shares in the Company (the "Offer Shares"), each with a par value of NOK 0.01, at a subscription price of NOK 8.10 per offer share (the "Subsequent Offering"), and (ii) the Transfer of Listing. Continue reading →